Literature DB >> 28295217

Randomized clinical trial of 270° posterior versus 180° anterior partial laparoscopic fundoplication for gastro-oesophageal reflux disease.

D J Roks1, J H Koetje2, J E Oor1, J A Broeders1, V B Nieuwenhuijs2, E J Hazebroek1.   

Abstract

BACKGROUND: Partial fundoplications provide similar reflux control with fewer post-fundoplication symptoms compared with Nissen fundoplication for gastro-oesophageal reflux disease (GORD). The best choice of procedure for partial fundoplication remains unclear. The aim of this study was to compare the outcome of two different types of partial fundoplication for GORD.
METHODS: A double-blind RCT was conducted between 2012 and 2015 in two hospitals specializing in antireflux surgery. Patients were randomized to undergo either a laparoscopic 270° posterior fundoplication (Toupet) or a laparoscopic 180° anterior fundoplication. The primary outcome was postoperative dysphagia at 12 months, measured by the Dakkak score. Subjective outcome was analysed at 1, 3, 6 and 12 months after surgery. Objective reflux control was assessed before and 6 months after surgery.
RESULTS: Ninety-four patients were randomized to laparoscopic Toupet or laparoscopic 180° anterior fundoplication (47 in each group). At 12 months, 85 patients (90 per cent) were available for follow-up. Objective scores were available for 76 (81 per cent). Postoperative Dakkak dysphagia score at 12 months was similar in the two groups (mean 5·9 for Toupet versus 6·4 for anterior fundoplication; P = 0·773). Subjective outcome at 12 months demonstrated no significant differences in control of reflux or post-fundoplication symptoms. Overall satisfaction and willingness to undergo surgery did not differ between the groups. Postoperative endoscopy and 24-h pH monitoring showed no significant differences in mean oesophageal acid exposure time or recurrent pathological oesophageal acid exposure.
CONCLUSION: Both types of partial fundoplication provided similar control of GORD at 12 months, with no difference in post-fundoplication symptoms. Registration number: NTR5702 (www.trialregister.nl).
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28295217     DOI: 10.1002/bjs.10500

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Reflux and Belching after Laparoscopic 270 degree Posterior Versus 180 degree Anterior Partial Fundoplication.

Authors:  J E Oor; J A Broeders; D J Roks; J M Oors; B L Weusten; A J Bredenoord; E J Hazebroek
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

2.  Comparison of Laparoscopic 270° Posterior Partial Fundoplication vs Total Fundoplication for the Treatment of Gastroesophageal Reflux Disease: A Randomized Clinical Trial.

Authors:  Bengt S Håkanson; Lars Lundell; Ami Bylund; Anders Thorell
Journal:  JAMA Surg       Date:  2019-06-01       Impact factor: 14.766

3.  Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries.

Authors:  John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

4.  Randomized clinical trial comparing laparoscopic hiatal hernia repair using sutures versus sutures reinforced with non-absorbable mesh.

Authors:  Jelmer E Oor; David J Roks; Jan H Koetje; Joris A Broeders; Henderik L van Westreenen; Vincent B Nieuwenhuijs; Eric J Hazebroek
Journal:  Surg Endosc       Date:  2018-05-15       Impact factor: 4.584

Review 5.  Assessing the efficacy and safety of laparoscopic antireflux procedures for the management of gastroesophageal reflux disease: a systematic review with network meta-analysis.

Authors:  Alexandros Andreou; David I Watson; Dimitrios Mavridis; Nader K Francis; Stavros A Antoniou
Journal:  Surg Endosc       Date:  2019-10-18       Impact factor: 4.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.